Welcome to the Dr Reddys Stock Liveblog, your ultimate source for real-time updates and analysis of one of the most prominent stocks in the market. Stay on top of the game with our comprehensive ...

Dr. Reddys Laboratories experiences a slight decrease of -0.09% in its monthly returns, despite a notable three-month return of 10.53%.

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1287.7, up 0.02% on the day ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is one of the Best Indian Stocks to Buy for Next 5 Years. Dr. Reddy’s ...

Hyderabad: Dr. Reddy’s Laboratories Ltd has announced an investment of Rs 565.4 crore in its step-down wholly owned ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

The company is going to announce results for the quarter ended June 30th, 2025 on July 23, 2025 after the board meeting.

The focus has now shifted to Semaglutide, the GLP-1 agonist being pursued as a generic version of Ozempic/Wegovy.

Dr. Reddy's Laboratories Ltd. closed 8.46% below its 52-week high of 1,420.20 rupees, which the company reached on August 21st.

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

Best case scenario, Semaglutide can garner $500 million sales in FY27, HSBC said. It added that Dr Reddy's will be among the ...